Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

Open access
Wakelee, Heather A, Dahlberg, Suzanne E, Keller, Steven M, Tester, William J, Gandara, David R, Graziano, Stephen L, Adjei, Alex A, Leighl, Natasha B, Aisner, Seena C, Rothman, Jan M, Patel, Jyoti D, Sborov, Mark D, McDermott, Sean R, Perez-Soler, Roman, Traynor, Anne M, Butts, Charles, Evans, Tracey, Shafqat, Atif, Chapman, Andrew E, Kasbari, Samer S, Horn, Leora, Ramalingam, Suresh S, Schiller, Joan H · 2017 · The Lancet Oncology

Abstract

SUMMARY Background Adjuvant chemotherapy for resected early stage NSCLC provides modest survival benefit. Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor, improves outcomes when added to platinum-based chemotherapy in advanced stage non-squamous NSCLC. We conducted a phase III study to evaluate the addition of bevacizumab to adjuvant chemotherapy in early stage resected NSCLC (E1505). The primary endpoint was overall survival. Methods Adult patients (≥ 18 years old) with ECOG performance status 0 or 1 with completely resected stage IB (≥4 centimeters) to IIIA (AJCC 6th edition) NSCLC were enrolled within 6–12 weeks of surgery and stratified by chemotherapy regimen, stage, histology, and sex. Minimum mediastinal lymph node sampling at specified levels was required (level 7 and 4 for right-sided tumors or level 7 and 5 and/or 6 for left-sided tumors). Normal laboratory values within two weeks of randomisation were required for enrollment. Chemotherapy, which was selected for each patient prior to randomisation, consisted of four, 3-week (21-day) cycles of cisplatin (75 mg/m2 in all regimens) with either vinorelbine 30 mg/m2 days 1 and 8; docetaxel 75 mg/m2 day 1; OR gemcitabine 1200 mg/m2 days 1 and 8; OR, starting in 2009 with an amendment, pemetrexed 500 mg/m2 day 1 along with B12 and folic acid supplementation. Patients were randomised 1:1 to Arm A (chemotherapy) or Arm B, adding bevacizumab at 15 mg/kg every 3 weeks starting with cycle 1 of chemotherapy and continuing for one year. Randomisation to treatment arm was performed centrally and determined using permuted blocks within strata with dynamic balancing on institution. The study had 85% power to detect a 21% reduction in the overall survival (OS) hazard rate with a one-sided 0·025-level test. The primary endpoint was overall survival, which was defined as the time from randomisation to death from any cause, and patients who were thought to be alive at the time of final analysis were censored at the last date of contact with analysis done based on intention to treat. This is final analysis of the primary endpoint of overall survival of E1505 (NCT00324805). Findings From July 2007 to September 2013, 1501 patients were enrolled, of whom 26% (N=383) had stage IB, 44% (N=636) stage II, and 30% (N=439) stage IIIA) with 28% (N=422) squamous cell histology. Cisplatin-based chemotherapy regimens utilized were vinorelbine 25% (N=377), docetaxel 23% (N=343), gemcitabine 19% (N=283), and pemetrexed 33% (N=497). At a median follow-up time of 50·3 months (IQR 32.9–68.0), estimated OS hazard ratio (B/A) was 0·99 (95% CI: 0·82–1·19, p=0·90). The median OS on Arm A has not been reached and is 85.8 months (95% CI 74.9-NA) on Arm B. Statistically significantly increased grade 3–5 toxicities of note (all attributions) included: overall worst grade (ie all grade 3/4/5 toxicities) (67%(N=496) versus 83%(N=610)); hypertension (8%(N=60) versus 30%(N=219)), and neutropenia (33%(N=241) versus 37%(N=275)) on Arms A and B, respectively. There was no significant difference in grade 5 adverse events per arm (N=15 on arm A and N=19 on arm B). Interpretation The addition of bevacizumab to adjuvant chemotherapy failed to improve overall survival for patients with surgically resected early stage NSCLC. Bevacizumab does not have a role in this setting and should not be considered as an adjuvant therapy for resected NSCLC patients. Funding This study was coordinated by the ECOG-ACRIN Cancer Research Group and supported by the National Cancer Institute of the National Institutes of Health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(17)30691-5

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 171

Metadata

Authors
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., Adjei, A. A., Leighl, N. B., Aisner, S. C., Rothman, J. M., Patel, J. D., Sborov, M. D., McDermott, S. R., Perez-Soler, R., Traynor, A. M., Butts, C., Evans, T., Shafqat, A., Chapman, A. E., Kasbari, S. S., Horn, L., Ramalingam, S. S., & Schiller, J. H.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2017-12
Volume
18
Issue
12
Pages
1610-1623
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2767470081
Cited by
171
References
2
FWCI
13.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(17)30691-5
The paper
Wakelee, H. A., Dahlberg, S. E., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., Adjei, A. A., Leighl, N. B., Aisner, S. C., Rothman, J. M., Patel, J. D., Sborov, M. D., McDermott, S. R., Perez-Soler, R., Traynor, A. M., Butts, C., Evans, T., Shafqat, A., Chapman, A. E., . . . Schiller, J. H. (2017). Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(17)30691-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.